In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model.
Omadacycline is an effective therapy for community-acquired bacterial pneumonia (CABP). Given its potent activity against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA), we sought to determine the pharmacodynamic activity and target PK/PD exposures associated with therapeutic effect in the neutropenic mouse pneumonia model against 10 MSSA/MRSA strains. The area under the concentration-time curve (AUC)/MIC associated with 1-log kill was noted at 24h ELF and plasma AUC/MIC exposures of ∼2 (ELF range <0.93 to 19, plasma range <1.06 to 17) and 2-log kill noted at 24h ELF and plasma AUC/MIC exposures of ∼12 (ELF range 2.5 to 130, plasma range 3.5 to 151).